A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Naïve Patients With Type 2 Diabetes Mellitus
Sponsor: Eli Lilly and Company
Listed as NCT01894568, this PHASE3 trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by Eli Lilly and Company, it has been updated 9 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aichi, Japan , Chiba, Japan , Daegu, South Korea , Fukuoka, Japan , Hokkaido, Japan , Hyōgo, Japan , Ibaraki, Japan , Incheon, South Korea , Kagawa, Japan , Kanagawa, Japan and 21 more locations